medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2005, Number 3

<< Back Next >>

Rev Biomed 2005; 16 (3)

History of Bone Marrow Transplant in Mexico.

Ruiz-Argüelles GJ

Language: Spanish
References: 61
Page: 207-214
PDF size: 69.61 Kb.


ABSTRACT

The transplant of parent haematopoyetic cells (TPHC) has become an indispensable therapeutic resource in modern medicine. In Mexico, TPHC transplants can be divided into two stages. The first stage began in 1980 when Dr. Ricardo Sosa and his team performed the first TPHC transplant at the Instituto Nacional de la Nutrición in Mexico City. After this transplant, some others were performed at the Centro Medico Nacional, the Hospital Universitario de Monterrey, México, and at the Instituto Nacional de la Nutrición itself, among other institutions, all with poor results. This resulted in the temporary suspension of TPHC programs in several hospitals throughout the country. The practice of TPHC became almost anecdotal until 1995. In that year the second stage began with the arrival of some doctors already trained in TPHC. Another factor causing the reactivation of TPHC programs was the development of knowledge in this area: a) PHC from peripheral blood was used instead of bone marrow; b) methods to carry out transplants were simplifíed, and; c) allotransplant with non-mieloblative conditioning schemes were introduced.
Non-mieloblative allogeneic transplants (NMAT) have found fertile ground in developing countries, Mexico among them, since they are much cheaper, simpler, and just as efficient. In 1999, a NMAT program began in Monterrey and Puebla using a new, cheap, and accessible scheme employing fludarabine, ciclofosfamide, and busulfan. This "Mexican" scheme has proven useful in transplants for children, adults, and elderly patients, and it has produced results similar to the "traditional" pre-transplant conditioning schemes. The accessibility and efficiency of this method have resulted in its adoption by several of the national institutions, including the Centro Médico de la Raza of the Mexican Institute of Social Security and the Instituto Nacional de Cancerología, and it has even been adopted as a reference method by the LACOHG (Latin American Cooperative Onco-Haemotology Group).
Umbilical cord cell transplants have taken place at the University Hospital of Monterrey, Mexico; the Haematology and Internal Medicine Center of Puebla; the Angeles Hospital of Mexico City and probably in other institutions. Placenta cell banks have been organized at the National Center of Blood Transfusion, the University Hospital of Monterrey, and the Cryopreservation Unit of Puebla, and in other private institutions.
The practice of TPHC in Mexico began in 1980, was stalled for some time, but luckily for the patients who require this treatment, it has recently restarted. In 2003, results of 1337 transplanted patients were reported nationwide.


REFERENCES

  1. 1.- Sosa-Sánchez R, Córdova MS, Labardini JR, Chávez-Peón F. Trasplante de médula ósea en anemia aplástica. Reporte del primer caso en México. Rev Invest Clin Mex 1980; 32:49-55.

  3. 2.- León-Rodríguez E, Sosa-Sánchez R, Gómez E, Ochoa-Sosa C.: Bone marrow transplantation in aplastic anemia: Experience at a Mexican institution. Rev Invest Clin Mex 1993; 45:559-64.

  5. 3.- León-Rodríguez E, Sosa-Sánchez R. Bone marrow transplantation in México. Report of the first succesful graft in acute myeloblastic leukemia. Grupo de trasplante medular óseo del INNSZ. Rev Invest Clin Mex 1992; 44:383-6.

  7. 4.- Morales-Polanco MR, Pizzuto-Chávez J. Bone marrow transplant in aplastic anemia. Current status and review of the first allogeneic transplants in México. Gac Med Mex 1984; 120:49-57.

  9. 5.- Delgado-Lamas JL, Garcés-Ruiz OM, Rubio-Jurado B. Hematopoietic cell transplantation: Experience at the Western National Medical Center. Rev Invest Clin 2000; 52:234-40.

  11. 6.- Vela-Ojeda J, Tripp-Villanueva F, Sánchez-Cortés E, Ayala-Sánchez M, Rosas-Cabral A, Esparza MG, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience. Arch Med Res 2000; 31:206-09.

  13. 7.- Reynoso-Gómez EE, Navarrete-Herrera Jr, Salinas-Rojas V, Sobrevilla-Calvo P, Miranda-López E. Experience with 22 bone marrow donors. Rev Invest Clin Mex 1997; 49:465-68.

  15. 8.- Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Ruiz-Argüelles A, Pérez-Romano B, Rivadeneyra L. Results of an autologous non-cryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: A single institution, 10-year experience. Acta Haematologica 2003; 110: 179-83.

  17. 9.- Ruiz-Argüelles GJ, Lobato-Mendizábal E, Ruiz-Argüelles A, Pérez-Romano B, Arizpe-Bravo D, Marín-López A. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotrasplant program: Long term results. Arch Med Res 1999; 30:380-4.

  19. 10.- Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Larregina-Díez A, Apreza-Molina MG. Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol 1995; 48:100-3.

  21. 11.- Ruiz-Argüelles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002; 76 (Suppl 1): 376-9.

  23. 12.- Ruiz-Argüelles GJ, Ruiz-Argüelles A, Gómez-Almaguer D, López-Martínez B, Abreu-Díaz G, Bravo G, Jaime-Pérez JC. Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intesity conditioning regimens. Leukemia Lymph 2001; 42: 145-50.

  25. 13.- Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-de-León S, Cantú-Rodríguez OG, Jaime-Pérez JC. Non cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology 2002; 7:95-9.

  27. 14.- Ruiz-Argüelles GJ, Gómez-Rangel JD, Ponce-de-León S, González-Déctor L, Reyes-Núñez V, Garcés-Eisele J. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease. Am J Hematol 2004; 75;200-4.

  29. 15.- Ruiz-Argüelles GJ, López-Martínez B, Santellán-Olea MR, Abreu-Díaz G, Reyes-Núñez V, Ruiz-Argüelles A, Garcés-Eisele J. Follow up of hemopoietic chimerism in individuals given allogeneic hemopoietic stem cell allografts using an immunosuppressive, non-myeloablative conditioning regimen: A prospective study in a single institution. Leukemia Lymph 2002; 43:1509-11.

  31. 16.- Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894-6.

  33. 17.- Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez Rancel JD, Vela-Ojeda J, Cantú-Rodríguez OG, Jaime-Pérez JC, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: A prospective study. Leukemia Lymphoma 2004; 45:1191-5.

  35. 18.- Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Llano O, Jaime-Pérez JC, López-Martínez B, et al. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transpl 2003; 9:157-61.

  37. 19.- Ruiz-Argüelles GJ, López-Martínez B, Gómez-Rangel D, Estrada E, Marín-López A, Bravo-Hernández G, et al. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: A single institution experience. Hematology 2003; 8: 151-4.

  39. 20.- Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25:131-3.

  41. 21.- Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hematol 2001; 66:241-4.

  43. 22.- Ruiz-Argüelles GJ, López-Martínez B, López-Ariza B. Succesful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin´s disease following autologous stem cell transplantation. Arch Med Res 2003; 34:242-5.

  45. 23.- Ruiz-Argüelles GJ. “The Mexican approach” to conduct non-myeloablative stem cell transplantation. Eur J Haematol 2001; 67:5-6.

  47. 24.- Gómez-Almaguer D. The simplification of the stem cell transplantation procedures in developing countries has resulted in cost-lowering and availability to more patients. Int J Hematol 2002; 76 (Suppl 1): 380-2.

  49. 25.- Ruiz-Argüelles GJ, Gómez-Rangel D, Sánchez-Anzaldo J, Ruiz-Argüelles A, Porras-Ramírez G, Luis-López A. Trasplante de células de cordón umbilical: Informe de dos casos. Medicina Univ 2002; 4:233-5.

  51. 26.- Ruiz-Argüelles GJ. Non-myeloablative bone marrow transplantation. Arch Med Res 2003; 34:554-7.

  53. 27.- Ruiz-Argüelles GJ, Gómez-Almaguer D. Breaking dogmata to help patients: Non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4:1693-9.

  55. 28.- Ruiz-Argüelles GJ, Reyes-Núñez V, Garcés-Eisele J, Warwick RM, McKenna L, Ruiz-Reyes G, et al. Acquired hemoglobin S trait in an adult patient with secondary acute myelogenous leukemia allografted with matched unrelated umbilical cord blood cells. Enviado a publicación.

  57. 29.- Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, Vela-Ojeda J, Karduss A, Cantú-Rodríguez OG, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia elegible for conventional allografting: a prospective study. Leuk Lymphoma 2004; 45: 1191-5.

  59. 30.- Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Morales E. Trasplante de células progenitoras hematopoyéticas. En Góngora-Biachi R. (editor) Hematología: Actualización 2004. Mérida: Ediciones de la Agrupación Mexicana para el Estudio de la Hematología A.C. 2004. pp. 139-48.

  61. 31.- Limón-Flores JA, González-Pérez ME, Lobato-Tolama RD, Valderrama-Bazán LG. Jornadas de trasplante hematopoyético en el IMSS de Puebla. Resultados. Rev Hematol 2004; 5 (Suppl 1): S11.




2020     |     www.medigraphic.com